A Randomized, Double-Blind, Parallel Arm Study of the Efficacy and Safety of Investigational Dulaglutide Doses When Added to Metformin in Patients With Type 2 Diabetes Mellitus
ClinicalTrials.gov NCT03495102
Research payments
$5,390,450
Through program year 2021, $5,390,450 in research payments was reported against A Randomized, Double-Blind, Parallel Arm Study of the Efficacy and Safety of Investigational Dulaglutide Doses When Added to Metformin in Patients With Type 2 Diabetes Mellitus, across 363 payments.
- Paid by (largest first)
- Eli Lilly and Company; Eli Lilly Export S.A. Puerto Rico Branch
- ClinicalTrials.gov
- NCT03495102
By program year
3 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2021 | Research | $6,515 | 5 |
| 2020 | Research | $85,069 | 98 |
| 2019 | Research | $5,298,866 | 260 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Eric Ball Walla Walla, WA Named on 6 payments
- Parvin Syal Simi Valley, CA Named on 5 payments
- Jane Rohlf Trenton, NJ Named on 5 payments
- Tami Bruce Mesa, AZ Named on 5 payments
- Thomas Knutson Green Bay, WI Named on 5 payments
- Sudhir Bansal Warwick, RI Named on 5 payments
- Paul Norwood Fresno, CA Named on 5 payments
- Cedrice Davis Marietta, GA Named on 5 payments
- Nabil Andrawis Manassas, VA Named on 4 payments
- Hanid Audish Spring Valley, CA Named on 4 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.